Mon, Jan 26, 2015, 6:57 AM EST - U.S. Markets open in 2 hrs 33 mins


% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • bhukap1116 bhukap1116 Jan 7, 2013 8:38 PM Flag

    Latest issue of journal of clinical oncology

    Editorial in the JCO points out the potential of Cabo as a MET/VEGF inhibitor in a variety of cancers and the importance of MET inhibition. Just another indication of the interest of very reputable people in Cabo

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This quote from the editorial (written about a P2 study of foretinib treatment in RCC) seems to indicate that cabo (Cometriq) has just the right combination of MET/VGFR inhibition. It seems a little unusual that in a study of one drug the author finds it necessary to point out another compound that works better and is more active in a number of different cancers.

      " Currently, there is growing interest in the activity of MET and VEGF as cooperative signals in tumor invasion and angiogenesis.5,6 These types of cooperative signaling interaction may account for some of the biologic activity seen with other multitargeted tyrosine kinase inhibitors such as cabozantinib, which has shown activity in castration-resistant prostate cancer,7 medullary thyroid cancer,8 hepatocellular carcinoma,9 and other settings. These findings bear high value if MET functions primarily as a somatic “adaptive” response to external pressure. The MET-VEGFR interaction in the tumor microenvironment bears particular interest given the high rate of pulmonary emboli in this study, perhaps implying a greater degree of vascular disruption."

      Sentiment: Strong Buy

      • 2 Replies to enabeler
      • Everything points to CABO being a big winner. As you quoted " such as cabozantinib, which has shown activity in castration-resistant prostate cancer,7 medullary thyroid cancer,8 hepatocellular carcinoma,9 and other settings." No amount of shorting, or twisting can hide those facts. This will be a multi billion dollar per year situation as it proves up, which because it is already approved will be far shorter than normal, and the clock is definitely ticking in favor of longs. All shorts or anyone else can do is play around very short term for a few cents. Upside will be huge as people realize what EXEL has here. Play or just get positioned and hold. It really is that simple. But if you can't handle volatility, you will get played with of course.

      • Thanks, enabeler! It should be noted that Exelixis does retain a board of consultants (unlike Geron or ACTC) that consists of experts in the areas Exelixis is working and are very influential. Positive comments in publications about Cabo may have been partly due to their involvement in Exelixis management.

    • Exactly. As the word leaks out, watch the speculation grow. And now the speculation is on Billion dollar annual markets. EXEL is about to move up in 2013 for that and many other reasons. Do not get fooled folks by volatility, as the potential here is blockbuster stuff, and speculation simply will not be contained.

      Sentiment: Strong Buy

1.63+0.01(+0.62%)Jan 23 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.